View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
August 27, 2020updated 12 Jul 2022 11:39am

Covid-19 Clinical Trials Continue to Rise in Brazil

The number of COVID-19 cases in Brazil has been on a steady increase since the beginning of April, hitting a peak high of confirmed new cases in early August. The number of total cases has surpassed 3.6 million with over 114,000 deaths.

By GlobalData Healthcare

The number of COVID-19 cases in Brazil has been on a steady increase since the beginning of April, hitting a peak high of confirmed new cases in early August. The number of total cases has surpassed 3.6 million with over 114,000 deaths.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Because of this, the number of COVID-19 clinical trials with a location in Brazil has also been increasing, with a marked steep incline since the beginning of June, as seen in Figure 1. There are currently 91 clinical trials with at least one location in Brazil. The majority are currently ongoing (72%), followed by planned (16.5%), completed (6.6%), and suspended/terminated/withdrawn with 4.4%. Of those trials that have been suspended/terminated/withdrawn, three quarters involved hydroxychloroquine as a primary intervention.

The country’s president, Jair Bolsonaro, is a vocal advocate of hydroxychloroquine and the drug was approved for widespread use across the country by the Health Minister in May for COVID-19. Therefore, it is not surprising that 10.8% of planned and ongoing trials include hydroxychloroquine as a primary intervention.

When looking at clinical trials in Brazil by phase, most are Phase III trials, followed by Phase II. Eight of these clinical trials are in the pivotal/registration stage, the final step before regulatory approval, assuming endpoints are met. These include two targeted therapies, tocilizumab and lenzilumab, as well as three small molecules, including remdesivir. The otherthree trials are for vaccines, which are two mRNA vaccines, BNT-162b1 and BNT-162b2, from BioNTech, and an inactivated vaccine, PiCoVacc, from Sinovac Biotech. Brazil recently approved human clinical trials for Ad26.COV2.S, on August 18, a potential COVID-19 vaccine that is being developed by Johnson & Johnson’s subsidiary Jensen.

The Phase III trial will enrol 60,000 patients, with 6,000 expected from Brazil. Ad26.COV2.S is a prophylactic vaccine that is administered with an intramuscular route of administration.

While the COVID-19 pandemic continues to cause high numbers of confirmed new cases in Brazil, the patient population available for the increasing number of clinical trials should allow these to continue to completion.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena